4-Aminopyridine
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06003166 | Apr 2025 → Dec 2027 expected | crush syndrome, peripheral nerve lesion | University of Arizona | Recruiting | No outcome recorded |
| Phase 2 | NCT03578354 | Jan 2019 → Jan 2023 | migraine disorder, vestibular disorder | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03658408 | Oct 2018 | prostate disorder | University of Rochester | Withdrawn | No outcome recorded |
| Phase 2 | NCT00056810 | Sep 2002 → May 2005 | Guillain-Barre syndrome | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 2 | NCT01543750 | — | episodic ataxia type 2 | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04026568 | Aug 2021 → Jul 2022 | traumatic neuropathy | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 2/3 | NCT03701581 | Jun 2021 → Jul 2027 expected | prostate cancer, traumatic neuropathy | John Elfar | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07532460 | Apr 2026 → Aug 2027 expected | cognitive disorder, substance-related disorder | Boris Quednow | Not yet recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT06294821 Comparator | Nov 2026 → Dec 2027 expected | carpal tunnel syndrome | John Elfar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06596434 Comparator | Jan 2026 → Jun 2028 expected | — | John Elfar | Recruiting | No outcome recorded |
| Phase 2 | NCT06333171 Comparator | Sep 2025 → Sep 2027 expected | — | John Elfar | Recruiting | No outcome recorded |
| Phase 2 | NCT02280096 Comparator | Oct 2014 → Feb 2016 | multiple sclerosis | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 2/3 | NCT01645787 Comparator | Jun 2012 → Sep 2015 | spinal muscular atrophy | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT03899584 Comparator | Jul 2019 → Dec 2022 | spinal cord injury | Coordinación de Investigación en Salud, Mexico | Unknown | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-Aminopyridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596434 ↗ |
| Known as | 4-AP | “This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of...” NCT03578354 ↗5“Recently, dalfampridine, an extended release formulation of 4AP (AMPYRA) by Acorda Therapeutics, received FDA approval to improve gait in multiple sclerosis.” NCT01543750 ↗ “The purpose of this study is to see if the study drug 4-aminopyridine (4-AP) can help speed up the recovery of peripheral nerve injury after prostatectomy.” NCT03658408 ↗ “immediate release formulation of 4-AP, sometimes called fampridine” NCT04026568 ↗ “4-aminopyridine (4-AP)” NCT00056810 ↗ “4-aminopyridine (4-AP)” NCT07532460 ↗ |
| Known as | AMPYRA | “The proposed version of the drug used in this study is an extended release formulation of 4-AP, called dalfampridine, which was marketed under the trade name AMPYRA, by Acorda...” NCT04026568 ↗1“Recently, dalfampridine, an extended release formulation of 4AP (AMPYRA) by Acorda Therapeutics, received FDA approval to improve gait in multiple sclerosis.” NCT01543750 ↗ |
| Known as | dalfampridine | “The proposed version of the drug used in this study is an extended release formulation of 4-AP, called dalfampridine, which was marketed under the trade name AMPYRA, by Acorda...” NCT04026568 ↗1“Recently, dalfampridine, an extended release formulation of 4AP (AMPYRA) by Acorda Therapeutics, received FDA approval to improve gait in multiple sclerosis.” NCT01543750 ↗ |
| Known as | fampridine | “immediate release formulation of 4-AP, sometimes called fampridine” NCT04026568 ↗ |
| Action | Inhibit | “4-aminopyridine (4-AP) in those patients who suffer chronic functional deficits from GBS.This medication is a potassium channel blocker” NCT00056810 ↗ |
| Route | Oral | “orally delivered 4-aminopyridine” NCT00056810 ↗ |